Loading...
Loading...
Mirati Therapeutics
MRTX today announced the appointment of Isan Chen, M.D., as chief medical and development officer as well as the appointment of Craig Johnson to its board of directors and as the chairman of the audit committee. Dr. Chen is a Board certified hematologist and oncologist who was most recently chief medical officer of Aragon Pharmaceuticals, which was acquired by Johnson & Johnson earlier this year. At Mirati, Dr. Chen will be responsible for leading the clinical development of multiple compounds in the Mirati pipeline that target some of the most promising genetic and epigenetic pathways in oncology. "Dr. Chen is an exceptional fit for Mirati's leadership that is built on expertise in targeted oncology, creativity in clinical development and a track record of successful oncology drug development," said Dr. Charles Baum, president and CEO of Mirati. "Together, the team is concentrating on innovative approaches to the development of our targeted oncology programs that focus on precisely defined patient populations. We are also pleased with the addition of Craig Johnson to our board of directors. Craig's biotechnology experience and financial background will be a valuable addition to the Mirati board."At Aragon,
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in